This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Fahl SP , Harris B , Coffey F , Wiest DL
Rpl22 Loss Impairs the Development of B Lymphocytes by Activating a p53-Dependent Checkpoint
J Immunol. 2015 Jan 1;194(1) :200-9
PMID: 25416806 PMCID: PMC4333014 URL: https://www.ncbi.nlm.nih.gov/pubmed/25416806
AbstractAlthough ribosomal proteins facilitate the ribosome's core function of translation, emerging evidence suggests that some ribosomal proteins are also capable of performing tissue-restricted functions either from within specialized ribosomes or from outside of the ribosome. In particular, we have previously demonstrated that germline ablation of the gene encoding ribosomal protein Rpl22 causes a selective and p53-dependent arrest of ab T cell progenitors at the b-selection checkpoint. We have now identified a crucial role for Rpl22 during early B cell development. Germline ablation of Rpl22 results in a reduction in the absolute number of B-lineage progenitors in the bone marrow beginning at the pro-B cell stage. Although Rpl22-deficient pro-B cells are hyporesponsive to IL-7, a key cytokine required for early B cell development, the arrest of B cell development does not result from disrupted IL-7 signaling. Instead, p53 induction appears to be responsible for the developmental defects, as Rpl22 deficiency causes increased expression of p53 and activation of downstream p53 target genes, and p53 deficiency rescues the defect in B cell development in Rpl22-deficient mice. Interestingly, the requirement for Rpl22 in the B cell lineage appears to be developmentally restricted, because Rpl22-deficient splenic B cells proliferate normally in response to Ag receptor and Toll receptor stimuli and undergo normal class-switch recombination. These results indicate that Rpl22 performs a critical, developmentally restricted role in supporting early B cell development by preventing p53 induction.
NotesFahl, Shawn P Harris, Bryan Coffey, Francis Wiest, David L eng R01 AI073920/AI/NIAID NIH HHS/ F32 AI098241/AI/NIAID NIH HHS/ R56 AI110985/AI/NIAID NIH HHS/ R56 AI073920/AI/NIAID NIH HHS/ R01 AI110985/AI/NIAID NIH HHS/ P30 CA006927/CA/NCI NIH HHS/ T32 CA009035/CA/NCI NIH HHS/ J Immunol. 2015 Jan 1;194(1):200-9. doi: 10.4049/jimmunol.1402242.